The $30 million recall: A safety concern for 3 million Britons

A batch of Ramipril 2.5mg capsules, manufactured by Crescent Pharma Limited, may contain strips of a higher dose , specifically Ramipril 10mg.. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an immediate recall of the affected batch, identified by code GR155023 on the packaging.

Packs of a popular blood pressure medication are being urgently recalled by health chiefs over patient safety concerns. Ramipril, for which there are 3 million prescriptions issed in the UK every month, is a medicine used to treat high blood pressure , kidney disease and heart failure.

What auditors flagged in the May filing

The Medicines and Healthcare products Regulatory Agency (MHRA) say that a batch of Ramipril 2.5mg, manufactured by Crescent Pharma Limited, may contain strips of a higher dose, specifically Ramipril 10mg.

According to the MHRA, patients who have the affected pack are being urged to take the leaflet supplied with their meidcine, along with any remaining capsules, to their pharmacy or GP practice for advice .

Who is the unnamed buyer?

The MHRA has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers .

The regulator has also issued an immediate recall of the affected batch, identified by code GR155023 on the packaging.

A familiar pattern from the 2019 crash

Ramipril is prescribed to around 3 million Britons every year and is a medicine used for high blood pressure, kidney disease and heart failure.

Those who take more than their prescribed dose of ramipril can also contact NHS 111 for advice, according to the health service's official guidance.

Open questions

The MHRA has not disclosed the identity of the unnamed buyer of the affected batch of Ramipril 2.5mg capsules.

The regulator has also not provided information on the total number of patients who may have been affected by the recall .

Broader context

The recall of Ramipril 2.5mg capsules is part of a broader trend of medication safety concerns in the UK.

In 2019, a batch of blood pressure medication was recalled due to contamination concerns.

The MHRA has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers.